Anti-thymocyte globulin versus basiliximab induction in renal : long-term outcome
المؤلفون المشاركون
Kesiraju, Sailaja
Paritala, Purna
Ch, Uma Maheswara Rao
Athmakuri, Srinivasa Murthy
Reddy V. S.
Sahariah S.
المصدر
Saudi Journal of Kidney Diseases and Transplantation
العدد
المجلد 25، العدد 1 (28 فبراير/شباط 2014)، ص ص. 9-15، 7ص.
الناشر
تاريخ النشر
2014-02-28
دولة النشر
السعودية
عدد الصفحات
7
التخصصات الرئيسية
الموضوعات
الملخص EN
Although basiliximab and rabbit anti-thymocyte globulin (ATG) are effective in delaying and reducing the incidence of acute rejection (AR) thus improving short-term graft survival, their impact on long-term graft survival has not been well established in renal transplant recipients.
To evaluate the long-term efficacy after induction therapy with ATG/basiliximab in renal transplant recipients, we studied retrospectively 86 renal transplant recipients of living donor renal transplantation from 2003 to 2006; of them, 42 patients received induction with ATG three doses of 50 mg, 25 mg, 25 mg/day on 0, 1 and 2 post-operative days (POD) and 44 agematched patients received induction with basiliximab (20 mg/day on 0 and 4 PODs).
All the patients received tacrolimus, mycophenolate mofetil and corticosteroids as maintenance immunosuppressive therapy.
Demographic characteristics were similar between both groups.
Patient survival at 5 years was 90.5% in the ATG group and 84.1% in the basiliximab group, while graft survival was 83.4% and 77.3%, respectively.
The incidence of acute rejection was 14.2% and 18.1% in the ATG and the basiliximab groups, respectively.
The estimated mean glomerular filtration rates at 5 years post-transplantation was 52.1 mL/min and 49.1 mL/min and the mean serum creatinine levels were 1.55 ± 0.37 and 1.66 ± 0.51 mg/dL in the ATG and basiliximab groups, respectively.
A low incidence of tuberculosis and cytomegalovirus (CMV) was observed in the ATG group.
There were no significant differences between the two groups, and both induction regimens assured a safe and effective treatment and were associated with similar excellent long-term patient and graft survival.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Kesiraju, Sailaja& Paritala, Purna& Ch, Uma Maheswara Rao& Athmakuri, Srinivasa Murthy& Reddy V. S.& Sahariah S.. 2014. Anti-thymocyte globulin versus basiliximab induction in renal : long-term outcome. Saudi Journal of Kidney Diseases and Transplantation،Vol. 25, no. 1, pp.9-15.
https://search.emarefa.net/detail/BIM-356458
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Kesiraju, Sailaja…[et al.]. Anti-thymocyte globulin versus basiliximab induction in renal : long-term outcome. Saudi Journal of Kidney Diseases and Transplantation Vol. 25, no. 1 (Jan. / Feb. 2014), pp.9-15.
https://search.emarefa.net/detail/BIM-356458
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Kesiraju, Sailaja& Paritala, Purna& Ch, Uma Maheswara Rao& Athmakuri, Srinivasa Murthy& Reddy V. S.& Sahariah S.. Anti-thymocyte globulin versus basiliximab induction in renal : long-term outcome. Saudi Journal of Kidney Diseases and Transplantation. 2014. Vol. 25, no. 1, pp.9-15.
https://search.emarefa.net/detail/BIM-356458
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 14-15
رقم السجل
BIM-356458
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر